We may never completely wipe out COVID-19, experts warn. Instead, we’ll work to minimize its spread and fend off the most dangerous strains, much like we do with the . So does that mean we’ll have to get for years to come? Perhaps. But we’ll have other ways to fight infections too, such as a drug from Merck and Ridgeback Biotherapeutics — an antiviral COVID pill awaiting US government approval.
The drug giant says the pill, called molnupiravir, can reduce the risk of hospitalization and death from COVID-19 by 50%. And unlike another antiviral drug already approved by the Food and Drug Administration that requires a needle, Merck says its medication can be taken orally to protect from severe illness.
In September, data from Johns Hopkins University showed that COVID-19 vaccines are highly effective, millions of Americans have not been vaccinated. According to a September report from the Centers for Disease Control and Prevention, unvaccinated people are over 10 times more likely to get hospitalized and die from the disease than fully vaccinated people.have died from the coronavirus. While the available
Here’s what we know about Merck’s antiviral drug right now. We’ll keep this story updated as more details emerge. For more on COVID-19, here’s the latest on, how to y and .
What is Merck’s COVID-19 antiviral drug?
COVID vaccines guard against infection. But for those already infected, antiviral drugs can lessen the serious effects of the disease, cutting the risk of hospitalization and death.
Antiviral drugs won’t replace the need for vaccines. Health officials see the two working side by side to keep infections in check: The vaccines prevent infection and lessen the severity of illness if you get infected. The antiviral can less the effects of the illness, regardless of vaccination status.
Merck isn’t the only pharmaceutical company making an antiviral pill for COVID-19. However, Merck’s pill is farther along in the process and could become the first antiviral drug approved to be taken orally and taken at home with a prescription. (See below for more on other antiviral drugs.)
A study of molnupiravir slashed the risk of hospitalization or death by 50% when given to non-hospitalized adult patients who tested positive for COVID-19, according to Merck.
When will the COVID pill be available?
The drug could be available by the end of 2021 if federal regulators don’t turn up any problems, The New York Times reported.
On Oct. 11, Merck applied for an emergency use authorization of its drug with the FDA. In anticipation of approval, Merck said it expects to produce 10 million courses by the end of 2021.
An FDA advisory committee is set to meet on Nov. 30 to consider the emergency use authorization.
How long would you have to take the COVID antiviral pill?
A course of the drug would require taking molnupiravir twice a day for five days.
Does taking an antiviral drug mean you don’t need a COVID-19 vaccine?
Vaccines and antiviral drugs serve different purposes. A vaccine is intended to provide powerful protection to keep you from getting COVID-19. An antiviral drug helps your body fight a virus if you get infected.
“The vaccine is our first-line tool for preventing hospitalization,” said Yale Medicine infectious diseases specialist Jaimie Meyer. “Some people might say, ‘I’m not getting vaccinated because I’ll have access to these medications,'” she said, “but you can’t trade one for the other.”
For example, chickenpox is a common virus that can be prevented in large part through vaccination. However, there are still cases of chickenpox that affect both vaccinated and unvaccinated people, and an antiviral medication may still be prescribed as a treatment. Taking that antiviral pill against the chickenpox won’t stop you from erupting into blisters all over your body, running a high fever, itching like crazy or being contagious. It won’t keep you from scarring, either. But it can help you recover a few days faster than you would have if you didn’t take the medication.
Will Merck’s antiviral drug be free?
That is the plan. The US government has purchased 1.7 million courses of the drug to provide for free if and when it is approved, much as it does now with the three approved vaccines from Pfizer, Moderna and Johnson & Johnson.
Who will be eligible for Merck’s antiviral pill?
In its tests, Merck’s molnupiravir pill was given to people who were unvaccinated and had tested positive with mild to moderate COVID-19 but were not hospitalized.
According to The New York Times, the drug may be available at first to those who have tested positive and are at higher risk of serious illness. The FDA and CDC will have the final say about who will be eligible for the pill.
Does the COVID pill have serious side effects?
According to Merck, data from the drug’s trials showed no serious side effects to the medication and the incidences of drug-related adverse effects were comparable between those taking molnupiravir and those taking the placebo.
We’ve reached out to Merck for more on possible side effects.
Are other antiviral COVID drugs in the works?
Yes. According to a New York Times tracker, one other antiviral drug has so far been approved for COVID-19 treatment — from Gilead Sciences, which was approved in October 2020. The Times is tracking 32 other possible drugs in different stages of development and approval.
Unlike Merck’s drug — which you can get from a pharmacist and take orally at home — Remdesivir requires a health care professional to give you the medication intravenously, through a needle. One dose can take 30 to 120 minutes to administer, and the drug is given once a day for 5 to 10 days, depending on the number of doses required.
For more on COVID-19, here’s the latest on, what to know about and what is happening with .
The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.
Business News Governmental News Finance News